PLoS ONE (Jan 2011)

Pax6 represses androgen receptor-mediated transactivation by inhibiting recruitment of the coactivator SPBP.

  • Julianne Elvenes,
  • Ernst Ivan Simon Thomassen,
  • Sylvia Sagen Johnsen,
  • Katrine Kaino,
  • Eva Sjøttem,
  • Terje Johansen

DOI
https://doi.org/10.1371/journal.pone.0024659
Journal volume & issue
Vol. 6, no. 9
p. e24659

Abstract

Read online

The androgen receptor (AR) has a central role in development and maintenance of the male reproductive system and in the etiology of prostate cancer. The transcription factor Pax6 has recently been reported to act as a repressor of AR and to be hypermethylated in prostate cancer cells. SPBP is a transcriptional regulator that previously has been shown to enhance the activity of Pax6. In this study we have identified SPBP to act as a transcriptional coactivator of AR. We also show that Pax6 inhibits SPBP-mediated enhancement of AR activity on the AR target gene probasin promoter, a repression that was partly reversed by increased expression of SPBP. Enhanced expression of Pax6 reduced the amount of SPBP associated with the probasin promoter when assayed by ChIP in HeLa cells. We mapped the interaction between both AR and SPBP, and AR and Pax6 to the DNA-binding domains of the involved proteins. Further binding studies revealed that Pax6 and SPBP compete for binding to AR. These results suggest that Pax6 represses AR activity by displacing and/or inhibiting recruitment of coactivators to AR target promoters. Understanding the mechanism for inhibition of AR coactivators can give rise to molecular targeted drugs for treatment of prostate cancer.